[Preclinical intervention in rheumatoid arthritis: balancing preventive benefits and clinical risks].

Authors

Y C Lyu, G Yin, Q B Xie, C J He

Published in

Zhonghua yi xue za zhi. Volume 106. Issue 33. Pages 3444-3450. Sep 08, 2026.

Abstract

Intervention in the preclinical of rheumatoid arthritis (Pre-RA) represents a core strategy for disease prevention and control. To date, there are no unified clinical standards regarding the timing and regimens of Pre-RA intervention. Non-pharmacological interventions are theoretically feasible yet lack support from high-quality randomized controlled trials. Pharmacological interventions are backed by more robust evidence-based data, though they carry both clinical benefits and potential risks. Risk stratification tools enable effective identification of patients at high risk of disease progression, though standardized clinical workflows for such tools have not yet been established. This article systematically reviews the available evidence and limitations of non-pharmacological and pharmacological interventions for pre-RA. On this basis, it comments on the clinical application of risk stratification tools and balances the benefits and risks of implementing early intervention strategies in pre-RA. Based on current evidence, a uniform strategy of aggressive intervention or watchful waiting is not recommended for the clinical management of pre-RA. Individualized precision interventions should be delivered according to risk stratification results combined with patient characteristics.

PMID:
42706130
Bibliographic data and abstract were imported from PubMed on 08 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.